Stimulation of lymphocytes of patients administered with a trypsin inhibitor, Trasylol (basic pancreatic trypsin inhibitor pharmaceutical), in vitro with BPTI and other several stimulants.
Distinguished lymphocytes stimulation was observed in vitro with one out of four patients received Trasylol therapy. The peak response of DNA synthesis was shown to occur at 100 mug/tube of basic pancreatic trypsin inhibitor (BPTI) itself, about 6 days after addition of BPTI. Reactivity (3H-thymidine incorporation) of lymphocytes of patients after the therapy, to specific antigen, ie., purified protein derivative (PPD) or Bordetella pertussis organisms in vitro, was markedly depressed. On the other hand, that to non-specific mitogen, phytohaemagglutinin-p of pokeweed mitogen, was a little reduced, or rather enhanced after the therapy. Conversly, lymphocytes of an originally tuberculin negative patient were lead to be stimulated with PPD in vitro, after skin test with PPD and Trasylol therapy. These various immune responses including drug-induced exanthemas of patients received the therapy, are discussed in this report, in comparison with immune responses of guinea pigs sensitized with BPTI, immune responses of animals in microorganism infections and the contrary immunological effects of Trasylol already reported.
D007611:Aprotinin / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D008934:Mitogens / Q000494:pharmacology; D010195:Pancreatitis / Q000188:drug therapy; D014373:Tuberculin / Q000494:pharmacology
D037102:Lectins; D008934:Mitogens; D014373:Tuberculin; D007611:Aprotinin